MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cam4.71124

Медицинская библиотека · Cancer medicine · 2025

Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post-Randomization Analysis.

Fattahi Sayeh, Chen Ming-Hui, Wu Jing, Smart Alicia C, D'Amico Anthony V

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

A low serum testosterone can prolong the time needed for PSA to exceed normal and prompt a work-up to rule out prostate cancer (PC), delaying diagnosis. We evaluated PC aggressiveness at diagnosis and PC-specific and all-cause mortality (PCSM, ACM)-risk within comorbidity subgroups in patients with low versus normal testosterone.

METHODS

Between 2005 and 2015, 350 PSA-screened patients with tumor (T) category1c-4N0M0 unfavorable-risk PC were enrolled in a randomized trial and comprised the study cohort. Fine and Gray and Cox multivariable regression analyses were used to evaluate PCSM and ACM risk, respectively, adjusting for age, known PC prognostic factors, randomized treatment arm, and the time-dependent use of salvage androgen deprivation therapy. An interaction term between the Adult Comorbidity Evaluation-27 defined comorbidity and low versus normal testosterone was included in the models to enable an assessment of PCSM and ACM risk within comorbidity subgroups in patients with low versus normal testosterone levels at randomization.

RESULTS

After a median follow up of 10.20 years, 89 of 350 patients died (25.43%) with 42 of 89 deaths (47.19%) from PC. In patients with no or minimal but not moderate to severe comorbidity, a significant association was observed between low compared to normal testosterone level at randomization and increased PCSM (AHR: 2.70 [95% CI: 1.27, 5.76], p = 0.01) and ACM risk (AHR: 1.90 [95% CI: 1.11, 3.26], p = 0.02).

CONCLUSION

Unlike PSA, multiparametric MRI (mpMRI) images are not influenced by the serum testosterone level; therefore, evaluating whether PCSM can be reduced by incorporating mpMRI into PC-screening in otherwise healthy men or transgender women with a low serum testosterone level should be considered.

TRIAL REGISTRATION: The statisical code used to derive the results from the interaction model for this post randomization analysis can be found in the Supporting Information.

Для цитирования: Fattahi Sayeh, Chen Ming-Hui, Wu Jing, Smart Alicia C, D'Amico Anthony V. Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post-Randomization Analysis.. Cancer medicine. 2025. DOI: 10.1002/cam4.71124.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.